Avalo Therapeutics (STU:C6K0) Cyclically Adjusted Book per Share: €418.53 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:C6K0 Avalo Therapeutics Inc STU:C6K0
44 GF Score
Price €15.76
GF Value €0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Cyclically Adjusted Book per Share?

Avalo Therapeutics STU:C6K0 -4.83% 44 Cyclically Adjusted Book per Share is €418.53 as of Mar. 2026. GuruFocus rates STU:C6K0 with a GF Score™ of 44/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Avalo Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €2.399. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €418.53 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Avalo Therapeutics's average Cyclically Adjusted Book Growth Rate was 50.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-23), Avalo Therapeutics's current stock price is €15.76. Avalo Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €418.53. Avalo Therapeutics's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Avalo Therapeutics was 0.04. The lowest was 0.01. And the median was 0.03.


Avalo Therapeutics  (STU:C6K0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Avalo Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=15.76/418.53
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Avalo Therapeutics was 0.04. The lowest was 0.01. And the median was 0.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Avalo Therapeutics Cyclically Adjusted Book per Share Related Terms


Avalo Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Cyclically Adjusted Book per Share Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -397.32 -10.17 494.16

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303.07 294.91 624.17 494.16 418.53

STU:C6K0 vs SANA, ANRO, REPL: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Avalo Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:C6K0
44GF Score
Avalo Therapeutics Inc STU:C6K0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Avalo Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.399/330.2130*330.2130
=2.399

Current CPI (Mar. 2026) = 330.2130.

Avalo Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 1,652.667 241.018 2,264.280
201609 174.333 241.428 238.444
201612 65.333 241.432 89.358
201703 -99.500 243.801 -134.766
201706 558.000 244.955 752.215
201709 2,062.111 246.819 2,758.847
201712 2,140.182 246.524 2,866.723
201803 1,812.455 249.554 2,398.263
201806 1,370.917 251.989 1,796.486
201809 1,194.143 252.439 1,562.047
201812 6.400 251.233 8.412
201903 7.124 254.202 9.254
201906 5.452 256.143 7.029
201909 5.760 256.759 7.408
201912 6.576 256.974 8.450
202003 18.120 258.115 23.181
202006 35.005 257.797 44.838
202009 25.520 260.280 32.377
202012 15.736 260.474 19.949
202103 21.622 264.877 26.955
202106 542.970 271.696 659.913
202109 878.538 274.310 1,057.580
202112 523.795 278.802 620.383
202203 147.667 287.504 169.603
202206 -144.359 296.311 -160.876
202209 -52.513 296.808 -58.423
202212 -264.205 296.797 -293.952
202303 -106.418 301.836 -116.423
202306 -110.897 305.109 -120.021
202309 17.168 307.789 18.419
202312 8.352 306.746 8.991
202403 -100.133 312.332 -105.866
202406 -12.226 314.175 -12.850
202409 1.961 315.301 2.054
202412 12.132 315.605 12.694
202503 10.475 319.799 10.816
202506 8.366 322.561 8.564
202509 4.375 324.800 4.448
202512 3.831 324.054 3.904
202603 2.399 330.213 2.399

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €418.53 mean?
Avalo Therapeutics (STU:C6K0) has a Cyclically Adjusted Book per Share of €418.53 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' Cyclically Adjusted Book per Share too high?
Avalo Therapeutics' current Cyclically Adjusted Book per Share is €418.53. Overall, Avalo Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Cyclically Adjusted Book per Share compare to SANA and ANRO?
Avalo Therapeutics' Cyclically Adjusted Book per Share of €418.53 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current Cyclically Adjusted Book per Share is €418.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (STU:C6K0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €15.76 — trading 52433.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is €418.53. Avalo Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Avalo Therapeutics (STU:C6K0), the current Cyclically Adjusted Book per Share is €418.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (STU:C6K0) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of €15.76 is trading 52433.3% above its estimated GF Value™ of €0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:C6K0:

  • Cyclically Adjusted Book per Share: €418.53
  • GF Value™: €0.03 vs. price of €15.76 (52433.3% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the STU:C6K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges AVTX:USA
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
44GF Score

Get the complete analysis for STU:C6K0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.76
Price
€0.03
GF Value